Author: admin

EU’s Decision To Remove UAE From List Of High-risk Third Countries In Money Laundering, Terrorist Financing, Reflects Wise Leadership’s Vision: CBUAE

(UrduPoint / Pakistan Point News / WAM – 10th Jul, 2025) ABU DHABI, 9th July, 2025 (WAM) – Khaled Mohamed Balama, Governor of the Central Bank of the United Arab Emirates (CBUAE), and Chairman of the National Committee for Anti-Money Laundering and Combatting the Financing of Terrorism and Illegal Organisations, stated that the European Union’s decision to remove the UAE’s name from the list of high-risk third countries in the area of money laundering and terrorist financing, reflects the vision of wise leadership.

‘’These aim at establishing an advanced financial ecosystem based on a forward-looking national vision and effective governance that ensures the safety and integrity of the financial sector,” said Balama in a statement following the EU’s decision.

He commended the diplomatic efforts led by H.H. Sheikh Abdullah Bin Zayed Al Nahyan, Deputy Prime Minister and Minister of Foreign Affairs, Chairman of the Higher Committee Overseeing the National Strategy on Anti-Money Laundering and Countering the Financing of Terrorism, which resulted in this important achievement.

This decision, he emphasised, reflects the UAE’s firm commitment to addressing challenges and risks in the financial system as a priority to enhance the UAE’s competitiveness and development journey.

‘’We appreciate the commitment of regulatory entities and authorities, licensed financial institutions and the private sector for their cooperation to achieve this progress and success for the UAE,’’ he added.

Continue Reading

July 9, 2025
BMW bosses unfairly dismissed disabled worker after spying on him | BMW

A disabled BMW worker was discriminated against and unfairly dismissed after bosses authorised covert surveillance on him, believing he was exaggerating his back pain, a tribunal has found.

Mohamed Kerita, who worked in the firm’s manufacturing factory, suffered with back pain from 2017, the tribunal in Reading heard.

In March 2023, a physiotherapist emailed the absence manager Richard Darvill to say that Kerita had been signed off work by his GP for two months.

The physiotherapist said he could not explain the level of pain Kerita was experiencing and why he remained unfit for work, the tribunal heard.

Darvill and the HR manager Akhil Patel instructed the security firm G4S to carry out surveillance of the claimant, which the employment judge, Emma Jane Hawksworth, said was a “highly unusual step”.

A G4S surveillance operative followed Kerita and filmed him from behind walking about three miles in about one and a half hours, even though the claimant never said he could not walk, the tribunal heard.

In a report, they said that there was “no indication whatsoever that the claimant had lower back, leg or shoulder pain or was experiencing sickness or dizziness”, despite not filming Kerita’s face.

Darvill later approached a senior manager to get more funding for further surveillance to ensure a “robust outcome”, the tribunal heard.

In May 2023, Kerita was dismissed for gross misconduct, including a fraudulent claim of company sick pay and unacceptable levels of absence.

During a disciplinary meeting, he had said that he was in the wrong area and needed light duties but his managers told him there were none and sent him home, the tribunal heard.

The tribunal found that Kerita’s back pain met the definition of a disability under the Equality Act 2010.

Judge Hawksworth said it could be inferred that managers “had a level of distrust or hostility towards associates with back conditions, and were unwilling to take their word for it that they had a back problem, or were quick to conclude that a person with a back condition was not being honest about their symptoms”.

The judge added: “We have found that the respondent made assumptions about what the claimant had told them about his ability to walk and about the G4S surveillance film.”

Kerita’s claims of failure to make reasonable adjustments, disability discrimination and unfair dismissal succeeded.

Continue Reading

July 9, 2025
OPEC+’s Supply Surprise Needed by Market, Middle East Oil Giants Say

Senior officials from three of OPEC’s core producer nations — Saudi Arabia, the United Arab Emirates, and Kuwait — lined up on Wednesday to say that the super-sized addition of supply by the producer club at the weekend was needed by the global market.

Oil prices eked out gains this week, a sign that the market has largely shrugged off the larger-than-expected output hike announced on Saturday by the Organization of the Petroleum Exporting Countries and allies. Despite the current tightness, forecasters are pointing out that supply growth is at risk of outpacing demand later in the year.

Continue Reading

July 9, 2025
What Are the Current COVID-19 Symptoms of the ‘Stratus’ Variant XFG?
A new variant of the continually mutating COVID-19 virus has health officials on alert as it spreads rapidly worldwide.

Nicknamed “Stratus,” the XFG strain was recently designated a “variant under monitoring” by the World Health Organization (WHO), as it accounts for a growing proportion of cases globally, particularly in Southeast Asia, where the new variant is connected to a simultaneous rise in new cases and hospitalizations.

Despite the uptick in illness, the WHO considers the overall public health risk from XFG to be low, and current data does not suggest that this variant leads to more severe illness or deaths than other variants in circulation.

“In most parts of the United States, we are in a pretty good place regarding respiratory illness, and most people should be enjoying their summer activities without too much worry,” says Mark Rupp, MD, a professor in the division of infectious diseases at the University of Nebraska Medical Center in Omaha.
Nationally, the wastewater viral activity level for COVID-19 is currently very low, according to the Centers for Disease Control and Prevention (CDC), but Dr. Rupp warns that, “with the XFG variant coming on the scene, this could start to bump up.”

Current COVID-19 Symptoms May Now Include Hoarseness

Experts expect XFG to cause symptoms similar to many previous variants, says Amy Edwards, MD, an assistant professor at the Case Western Reserve University School of Medicine in Cleveland who specializes in pediatric infectious diseases.

Typical COVID-19 symptoms include the following:

Several media outlets have reported that people who are infected with the new variant are also experiencing hoarseness or a dry, irritated throat among the main effects of the virus.

Dr. Edwards, however, doesn’t view hoarseness as particularly unique to XFG. “There are a number of variants that have been causing sore throat or hoarse voice,” she says. “All respiratory viruses can do this, along with all the other usual symptoms, such as cough, runny nose, and fever.”

Fewer People Are Reporting Their COVID-19 Infections

The latest CDC tracking shows that XFG is responsible for about 14 percent of recent COVID cases, while variants NB.1.8.1 and LP.8.1 account for nearly three-quarters of reported infections.

The CDC cautions that due to the low number of infections reported, precision in the most recent reporting period is low. Walgreens also offers a tracker of respiratory illness trends based on its consumer data, but Dr. Rupp warns that Walgreens’ tracking suffers from some of the same limitations as the CDC’s system and does not offer detailed sequencing information.

“As most folks with COVID do not get tested, or they use home test kits that are not reported, the data we have in the public health sequencing system is pretty scant and lags behind,” says Dr. Rupp.

COVID-19 Can Still Make You Unpleasantly Sick

The WHO stresses that the Stratus variant does not appear to cause more severe illness than recent previous strains.

Edwards suspects that COVID-19 cases may rise as the summer continues, but she doesn’t expect the situation to be any worse than last year.

Also, while COVID may not be causing as many life-threatening illnesses as in the past, she says that even a mild-seeming infection can be fairly bad compared with other respiratory illnesses. “This is probably because by now everyone has had COVID at least once or had multiple vaccines, so the virus is no longer novel to the body’s immune system,” says Edwards.

Public health authorities underscore that vaccination still offers strong protection against extreme illness. “Currently approved COVID-19 vaccines are expected to remain effective to this variant against symptomatic and severe disease,” writes the WHO.

The CDC recommends staying up to date on COVID-19 vaccines, as they significantly lower the risk of getting very sick, being hospitalized, or dying from COVID-19.

The agency also urges all people to protect themselves with these habits:

Practicing good hygiene, including regular hand-washing

Staying home and away from others, including people you live with who are not sick, if you have respiratory symptoms

Seeking healthcare promptly for testing or treatment if you have risk factors for severe illness

Wearing a mask can help lower the risk of transmission
Continue Reading
July 9, 2025
‘Duster’ Canceled By HBO Max After One Season

EXCLUSIVE: After a five-year build-up, it was a short run for Bad Robot’s 1970s crime drama Duster as HBO Max is not proceeding with a second season of the series from J.J. Abrams and LaToya Morgan. The news comes less than a week after the Season 1 finale debuted on the platform.

It is not entirely surprising because Duster, starring Josh Holloway and Rachel Hilson, wasn’t able to generate a lot of buzz and viewer interest. Those who tuned in, largely liked what they saw — Duster is averaging 92% among critics and 83% among general viewers on Rotten Tomatoes. The series from Warner Bros. and Abrams’ studio-based Bad Robot also remains in the daily Top 10 on HBO Max but it has not been able to get into the Nielsen Top 10 for streaming originals and barely cracked Luminate’s list of Top 50 streaming originals in its fourth week at the last #50 spot.

“While HBO Max will not be moving forward with a second season of Duster, we are so grateful to have had the chance to work with the amazingly talented co-creators J.J. Abrams and LaToya Morgan, and our partners at Bad Robot and Warner Bros. Television,” HBO Max said in a statement to Deadline. “We are tremendously proud of this series led by Josh Holloway and Rachel Hilson and we thank them along with our cast and crew for their incredible collaboration and partnership.”

Duster, which reunited Lost co-creator/executive producer Abrams and star Holloway, was originally ordered in April 2020. It filmed awhile ago, so the options on the cast already had expired and were not extended (which is not highly unusual for HBO Max), sources said.

Seeing the writing on the wall, I hear WBTV and Bad Robot quietly shopped Duster to other platforms where the adrenaline-heavy series could’ve been a better fit but the effort was unsuccessful.

Duster follows Nina (Hilson), the first Black female FBI agent, who in 1972 heads to the Southwest and recruits a gutsy getaway driver (Holloway), the first in a bold effort to take down a growing crime syndicate.

Keith David, Sydney Elisabeth, Greg Grunberg, Camille Guaty, Asivak Koostachin, Adriana Aluna Martinez, and Benjamin Charles Watson also starred.

“J.J. Abrams and LaToya Morgan delivered a thrilling, multi-dimensional crime drama in Duster, with textured characters that took the audience back to the 1970s in a new and innovative way,” WBTV said in a statement to Deadline. “Those characters were brought to life by a wonderful team led by Josh, Rachel, and an extremely talented ensemble cast, along with an expert crew behind the scenes. We are incredibly proud of the show, and while we wish this journey could continue, we are thankful to our partners at HBO Max for the opportunity to tell Jim and Nina’s story.”

The first two episodes of Duster were written by Abrams and Morgan and directed by and executive produced by Steph Green. The series was executive produced by Abrams and Rachel Rusch Rich for Bad Robot and Morgan for TinkerToy Productions.

As HBO Max canceled Duster, the streamer today picked up The Big Bang Theory spinoff series Stuart Fails To Save The Universe, also from WBTV.

Continue Reading

July 9, 2025
‘Harmless’ virus might trigger Parkinson’s disease, researchers say

July 9 (UPI) — A common virus once thought harmless to humans might be linked to Parkinson’s disease, a new study says.

The germ, Human Pegivirus (HPgV), was found in half the autopsied brains of patients with Parkinson’s, but not in any brains from healthy people, researchers reported Tuesday in the journal JCI Insight.

“HPgV is a common, symptomless infection previously not known to frequently infect the brain,” lead researcher Dr. Igor Koralnik, chief of neuroinfectious diseases and global neurology at Northwestern Medicine in Chicago, said in a news release.

“We were surprised to find it in the brains of Parkinson’s patients at such high frequency and not in the controls.”

The virus also appeared to prompt different responses from people’s immune systems, depending on their genetics, Koralnik said.

“This suggests it could be an environmental factor that interacts with the body in ways we didn’t realize before,” Koralnik said. “For a virus that was thought to be harmless, these findings suggest it may have important effects, in the context of Parkinson’s disease. It may influence how Parkinson’s develops, especially in people with certain genetic backgrounds.”

Parkinson’s disease occurs when brain cells that produce an important hormone called dopamine begin to die off or become impaired.

As dopamine levels decrease, people develop movement symptoms like shaking or stiffness, as well as problems maintaining balance and coordination.

More than 1 million people in the U.S. live with Parkinson’s disease, including actors Michael J. Fox and Alan Alda, singer Neil Diamond and football great Brett Favre. About 90,000 new cases are diagnosed every year, researchers said.

Most cases of Parkinson’s are not linked to a person’s genetics, raising the question of what might trigger the death of dopamine-producing nerve cells, researchers said in background notes.

For the new study, researchers autopsied the brains of 10 Parkinson’s patients and 14 people not suffering from the disorder.

The team found HPgV in 5 out of 10 brains from people with Parkinson’s, but none of the 14 healthy brains. The virus also was present in the spinal fluid of Parkinson’s patients, but not in the control group.

Further, more brain damage was found in patients with HPgV, researchers said.

Next, researchers tested blood samples from more than 1,000 participants in the Parkinson’s Progression Markers Initiative, a biosample library available for Parkinson’s research. HPgV is a blood-borne virus in the same family as hepatitis C.

Only about 1% of Parkinson’s patients had HPgV in their blood samples, researchers found.

But people who had the virus showed different signals from their immune system, particularly those with a Parkinson’s-related gene mutation called LRRK2, researchers said.

“We plan to look more closely at how genes like LRRK2 affect the body’s response to other viral infections to figure out if this is a special effect of HPgV or a broader response to viruses,” Koralnik said.

Researchers plan to continue tracking how common the virus is among Parkinson’s patients, and how it might trigger the brain disorder.

“One big question we still need to answer is how often the virus gets into the brains of people with or without Parkinson’s,” Koralnik said. “We also aim to understand how viruses and genes interact; insights that could reveal how Parkinson’s begins and could help guide future therapies.”

More information

The National Institute on Aging has more about Parkinson’s disease.

Copyright © 2025 HealthDay. All rights reserved.

Continue Reading

July 9, 2025
CEO charged with bid rigging in University of Texas arena project

Oak View Group CEO Tim Leiweke was indicted on a federal criminal conspiracy charge related to allegedly rigging a bid to develop, manage, and operate the University of Texas’ basketball and entertainment arena in Austin, the Department of Justice said Wednesday.

Oak View Group, which will pay $15 million in penalties in connection with the allegations, later Wednesday said that Leiweke “will transition from the position of CEO to” vice chairman of the entertainment venue giant’s board of directors, and remain a shareholder.

Leiweke, 68, is accused in the indictment of conspiring with another would-be bidder on UT’s $338 million Moody Center arena project to induce that second company in February 2018 to drop out of the competition with Oak View Group in exchange for receiving lucrative subcontracts at the 15,000-seat arena.

CNBC has been told the second company was Legends Hospitality, a New York-based venue services company that is majority-owned by Sixth Street Partners, and whose minority owners include the New York Yankees and the Dallas Cowboys.

The indictment in U.S. District Court in Austin says that Leiweke later reneged on that promise to the second company after it dropped its effort to bid on the entire project.

“The arena opened to the public in April 2022, and OVG continues to receive significant revenues from the project to date,” the Department of Justice said Wednesday.

Leiweke “rigged a bidding process to benefit his own company and deprived a public university and taxpayers of the benefits of competitive bidding,” said Assistant Attorney General Abigail Slater of the DOJ’s Antitrust Division, in a statement.

Leweike, in a 2022 interview with CNBC, said that the Moody Center was one of his company’s “two most successful arenas.”

The DOJ also said Wednesday that Oak View Group and Legends agreed to pay $15 million and $1.5 million, respectively, in penalties “in connection with the conduct alleged in the indictment against Leiweke.”

Oak View Group’s website says that the company manages 400 sports, entertainment and other venues.

Lewieke, who is charged with one count of conspiracy to restrain trade, is the former CEO of Maple Leaf Sports and Entertainment. Before that, he served as CEO of Anschutz Entertainment Group.

A spokesman for Leiweke, in a statement to CNBC, said, “Mr. Leiweke has done nothing wrong and will vigorously defend himself and his well-deserved reputation for fairness and integrity.”

“The Antitrust Division’s allegations are wrong on the law and the facts, and the case should never have been brought,” the spokesman said. “The law is clear: vertical, complementary business partnerships, like the one contemplated between OVG and Legends, are legal.”

“These allegations blatantly ignore established legal precedent and seek to criminalize common teaming efforts that are proven to enhance competition and benefit the public. The Moody Center is a perfect example, as it has resulted in substantial and sustained benefits to the University of Texas and the City of Austin.”

Leiweke, in his own statement, said, “While I’m pleased the company has resolved its Department of Justice Antitrust Division inquiry without any charges filed or admission of wrongdoing, the last thing I want to do is distract from the accomplishments of the team or draw focus away from executing for our partners, so the Board and I decided that now is the right time to implement the succession plan that was already underway and transition out of the CEO role.

Oak View Group, in a statement, said, “Oak View Group cooperated fully with the Antitrust Division’s inquiry and is pleased to have resolved this matter with no charges filed against OVG and no admission of fault or wrongdoing.”

“We support all efforts to ensure a fair and competitive environment in our industry and are committed to upholding industry-leading compliance and disclosure practices,” Oak View Group said.

CNBC has requested comment from Legends.

Chris Granger, who was president of Oak View Group’s division OVG360, has been appointed as interim CEO of Oak View Group by the company’s board.

Granger previously was group president for sports and entertainment of the Detroit Tigers and Detroit Red Wings, and president and chief operating officer of the Sacramento Kings.

Continue Reading

July 9, 2025
The economic burden of malaria in Africa: a systematic review of cost of illness studies | Malaria Journal
WHO. Economic costs of malaria. Geneva, World Health Organization, 2011.
Worrall E, Basu S, Hanson K. Is malaria a disease of poverty? A review of the literature. Trop Med Int Health. 2005;10:1047–59.

CAS
PubMed

Google Scholar
Wafula ST, Habermann T, Franke MA, May J, Puradiredja DI, Lorenz E, et al. What are the pathways between poverty and malaria in sub-Saharan Africa? A systematic review of mediation studies. Infect Dis Poverty. 2023;12:58.

PubMed
PubMed Central

Google Scholar
Sicuri E, Vieta A, Lindner L, Constenla D, Sauboin C. The economic costs of malaria in children in three sub-Saharan countries: Ghana, Tanzania and Kenya. Malar J. 2013;12:307.

PubMed
PubMed Central

Google Scholar
Asante FA, Asenso-Okyere K. Economic burden of malaria in Ghana. Technical report submitted to the World Health Organization, African Region. 2003;1–81.
Adjagba A, Onwujekwe O, Bocoum F, Osei-Akoto I, Matovu F. Economic cost of malaria in four countries in sub-Saharan Africa: a comparative analysis. Afr J Health Economics. 2019;8:23–33.

Google Scholar
Watts C, Atieli H, Alacapa J, Lee M-C, Zhou G, Githeko A, et al. Rethinking the economic costs of hospitalization for malaria: accounting for the comorbidities of malaria patients in western Kenya. Malar J. 2021;20:429.

PubMed
PubMed Central

Google Scholar
Obieche OA, Odili VU. Evaluation of cost of treatment of malaria in adults in Benin City, Nigeria: patients’ perspective. Malariaworld J. 2016;7:12.

PubMed
PubMed Central

Google Scholar
Chima RI, Goodman CA, Mills A. The economic impact of malaria in Africa: a critical review of the evidence. Health Policy. 2003;63:17–36.

PubMed

Google Scholar
El-Houderi A, Constantin J, Castelnuovo E, Sauboin C. Economic and resource use associated with management of malaria in children aged < 5 years in sub-Saharan Africa: a systematic literature review. MDM Policy Pract. 2019;4:2381468319893986.

PubMed
PubMed Central

Google Scholar
Andrade MV, Noronha K, Diniz BP, Guedes G, Carvalho LR, Silva VA, et al. The economic burden of malaria: a systematic review. Malar J. 2022;21:283.

PubMed
PubMed Central

Google Scholar
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.

PubMed
PubMed Central

Google Scholar
CCEMG-EPPI-Centre cost converter; Version 1.7: The Campbell and Cochrane Economics Methods Group (CCEMG) and the Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre). https://eppi.ioe.ac.uk/costconversion/.
Yukich JO, Lengeler C, Tediosi F, Brown N, Mulligan JA, Chavasse D, et al. Costs and consequences of large-scale vector control for malaria. Malar J. 2008;7:258.

PubMed
PubMed Central

Google Scholar
Temperley M, Mueller DH, Njagi JK, Akhwale W, Clarke SE, Jukes MC, et al. Costs and cost-effectiveness of delivering intermittent preventive treatment through schools in western Kenya. Malar J. 2008;7:196.

PubMed
PubMed Central

Google Scholar
Scates SS, Finn TP, Wisniewski J, Dadi D, Mandike R, Khamis M, et al. Costs of insecticide-treated bed net distribution systems in sub-Saharan Africa. Malar J. 2020;19:105.

PubMed
PubMed Central

Google Scholar
Salawu AT, Fawole OI, Dairo MD. Patronage and cost of malaria treatment in private hospitals in Ibadan North L.G.A. South Western, Nigeria. An Ib Postgrad Med. 2016;14:81–4.

CAS

Google Scholar
Nonvignon J, Aryeetey GC, Malm KL, Agyemang SA, Aubyn VN, Peprah NY, et al. Economic burden of malaria on businesses in Ghana: a case for private sector investment in malaria control. Malar J. 2016;15:454.

PubMed
PubMed Central

Google Scholar
Sicuri E, Yaya Bocoum F, Nonvignon J, Alonso S, Fakih B, Bonsu G, et al. The costs of implementing vaccination with the RTS, S malaria vaccine in five sub-Saharan African countries. MDM Policy Pract. 2019;4:2381468319896280.

PubMed
PubMed Central

Google Scholar
Devine A, Pasaribu AP, Teferi T, Pham HT, Awab GR, Contantia F, et al. Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data. Bull World Health Organ. 2019;97:828–36.

PubMed
PubMed Central

Google Scholar
Mosha JF, Conteh L, Tediosi F, Gesase S, Bruce J, Chandramohan D, et al. Cost implications of improving malaria diagnosis: findings from north-eastern Tanzania. PLoS ONE. 2010;5: e8707.

PubMed
PubMed Central

Google Scholar
Okogun GR, Amadi AN. Epidemiology, therapeutic agents and cost of management of paediatric malaria in a Nigerian tertiary hospital. J Vector Borne Dis. 2005;42:87–94.

PubMed

Google Scholar
Chuma JM, Thiede M, Molyneux CS. Rethinking the economic costs of malaria at the household level: evidence from applying a new analytical framework in rural Kenya. Malar J. 2006;5:76.

PubMed
PubMed Central

Google Scholar
Stovold E, Beecher D, Foxlee R, Noel-Storr A. Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram. Syst Rev. 2014;3:54.

PubMed
PubMed Central

Google Scholar
Batura N, Kasteng F, Condoane J, Bagorogosa B, Castel-Branco AC, Kertho E, et al. Costs of treating childhood malaria, diarrhoea and pneumonia in rural Mozambique and Uganda. Malar J. 2022;21:239.

PubMed
PubMed Central

Google Scholar
Cirera L, Sacoor C, Meremikwu M, Ranaivo L, FME M, Arikpo D, et al. The economic costs of malaria in pregnancy: evidence from four sub-Saharan countries. Gates Open Res. 2023;7:47.

PubMed
PubMed Central

Google Scholar
Diawara H, Bocoum FY, Dicko A, Levin A, Lee C, Koita F, et al. Cost of introducing and delivering malaria vaccine (RTS, S/AS01(E)) in areas of seasonal malaria transmission, Mali and Burkina Faso. BMJ Gobal Health. 2023;8: e011316.

Google Scholar
Duval L, Sicuri E, Scott S, Traoré M, Daabo B, Tinto H, et al. Household costs associated with seeking malaria treatment during pregnancy: evidence from Burkina Faso and The Gambia. Cost Eff Resour Alloc. 2022;20(1):42.

PubMed
PubMed Central

Google Scholar
Tsehay S, Hassen F, Hirigo AT, Abiy Z, Desta K. Blood transfusion-transmissible malaria and its cost analysis in Hawassa regional blood bank, Southern Ethiopia. SAGE Open Med. 2020;8:2050312120936930.

PubMed
PubMed Central

Google Scholar
Tefera DR, Sinkie SO, Daka DW. Economic burden of malaria and associated factors among rural households in Chewaka district, Western Ethiopia. Clinicoecon Outcomes Res. 2020;12:141–52.

PubMed
PubMed Central

Google Scholar
Somi MF, Butler JR, Vahid F, Njau JD, Kachur SP, Abdulla S. Economic burden of malaria in rural Tanzania: variations by socioeconomic status and season. Trop Med Int Health. 2007;12:1139–47.

PubMed

Google Scholar
Rahman R, Lesser A, Mboera L, Kramer R. Cost of microbial larviciding for malaria control in rural Tanzania. Trop Med Int Health. 2016;21:1468–75.

PubMed
PubMed Central

Google Scholar
Phiri MD, McCann RS, Kabaghe AN, van den Berg H, Malenga T, Gowelo S, et al. Cost of community-led larval source management and house improvement for malaria control: a cost analysis within a cluster-randomized trial in a rural district in Malawi. Malar J. 2021;20:268.

PubMed
PubMed Central

Google Scholar
Masimbi O, Schurer JM, Rafferty E, Ndahimana JA, Amuguni JH. A cost analysis of the diagnosis and treatment of malaria at public health facilities and communities in three districts in Rwanda. Malar J. 2022;21:150.

PubMed
PubMed Central

Google Scholar
Kodhiambo MO, Oyugi JO, Amugune BK. Modelling the household cost of paediatric malaria treatment in a rural county in Kenya: do non-user fee payments matter? A partial cost of illness analysis. BMJ Open. 2020;10: e033192.

PubMed
PubMed Central

Google Scholar
Hennessee I, Chinkhumba J, Briggs-Hagen M, Bauleni A, Shah MP, Chalira A, et al. Household costs among patients hospitalized with malaria: evidence from a national survey in Malawi, 2012. Malar J. 2017;16:395.

PubMed
PubMed Central

Google Scholar
Hardy A, Haji K, Abbas F, Hassan J, Ali A, Yussuf Y, et al. Cost and quality of operational larviciding using drones and smartphone technology. Malar J. 2023;22:286.

PubMed
PubMed Central

Google Scholar
Hailu A, Lindtjørn B, Deressa W, Gari T, Loha E, Robberstad B. Economic burden of malaria and predictors of cost variability to rural households in south-central Ethiopia. PLoS ONE. 2017;12: e0185315.

PubMed
PubMed Central

Google Scholar
Guyatt HL, Kinnear J, Burini M, Snow RW. A comparative cost analysis of insecticide-treated nets and indoor residual spraying in highland Kenya. Health Policy Plan. 2002;17:144–53.

CAS
PubMed

Google Scholar
Gunda R, Shamu S, Chimbari MJ, Mukaratirwa S. Economic burden of malaria on rural households in Gwanda district, Zimbabwe. Afr J Prim Health Care Fam Med. 2017;9:e1–6.

PubMed

Google Scholar
Drake TL, Okello G, Njagi K, Halliday KE, Jukes M, Mangham L, et al. Cost analysis of school-based intermittent screening and treatment of malaria in Kenya. Malar J. 2011;10:273.

PubMed
PubMed Central

Google Scholar
Deressa W, Hailemariam D, Ali A. Economic costs of epidemic malaria to households in rural Ethiopia. Trop Med Int Health. 2007;12:1148–56.

PubMed

Google Scholar
Canana N. A cost analysis to address issues of budget constraints on the implementation of the indoor residual spray programme in two districts of Maputo Province, Mozambique. Malar J. 2021;20:8.

PubMed
PubMed Central

Google Scholar
Ayieko P, Akumu AO, Griffiths UK, English M. The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malaria and meningitis. Cost Eff Resour Alloc. 2009;7:3.

PubMed
PubMed Central

Google Scholar
Abdel-Hameed AA, Abdalla HM, Alnaury AH. Household expenditure on malaria case management in Wad-Medani, Sudan. Afr J Med Med Sci. 2001;30(Suppl):35–8.

PubMed

Google Scholar
Broekhuizen H, Fehr A, Nieto-Sanchez C, Muela J, Peeters-Grietens K, Smekens T, et al. Costs and barriers faced by households seeking malaria treatment in the Upper River Region. The Gambia Malar J. 2021;20:368.

PubMed

Google Scholar
Castellani J, Mihaylova B, Siribié M, Gansane Z, Ouedraogo AZ, Fouque F, et al. Household costs and time to treatment for children with severe febrile illness in rural Burkina Faso: the role of rectal artesunate. Malar J. 2018;17:380.

PubMed
PubMed Central

Google Scholar
Dalaba MA, Welaga P, Oduro A, Danchaka LL, Matsubara C. Cost of malaria treatment and health seeking behaviour of children under-five years in the Upper West Region of Ghana. PLoS ONE. 2018;13: e0195533.

PubMed
PubMed Central

Google Scholar
Dambach P, Schleicher M, Stahl HC, Traoré I, Becker N, Kaiser A, et al. Routine implementation costs of larviciding with Bacillus thuringiensis israelensis against malaria vectors in a district in rural Burkina Faso. Malar J. 2016;15:380.

PubMed
PubMed Central

Google Scholar
De Allegri M, Marschall P, Flessa S, Tiendrebéogo J, Kouyaté B, Jahn A, et al. Comparative cost analysis of insecticide-treated net delivery strategies: sales supported by social marketing and free distribution through antenatal care. Health Policy Plan. 2010;25(1):28–38.

PubMed

Google Scholar
Ezenduka CC, Falleiros DR, Godman BB. Evaluating the treatment costs for uncomplicated malaria at a public healthcare facility in Nigeria and the implications. PharmacoEconomics – open. 2017;1(3):185–94.

PubMed
PubMed Central

Google Scholar
Ismail NE, Jimam NS, Goh KW, Tan CS, Ming LC. Economic Burdens of Uncomplicated Malaria in Primary Health Care (PHC) Facilities of Plateau State, Nigeria: Patients’ Perspectives. International journal of environmental research and public health. 2023;20(2).
Kahn JG, Harris B, Mermin JH, Clasen T, Lugada E, Grabowksy M, et al. Cost of community integrated prevention campaign for malaria, HIV, and diarrhea in rural Kenya. BMC Health Serv Res. 2011;11:346.

PubMed
PubMed Central

Google Scholar
Maccario R, Rouhani S, Drake T, Nagy A, Bamadio M, Diarra S, et al. Cost analysis of a school-based comprehensive malaria program in primary schools in Sikasso region, Mali. BMC Public Health. 2017;17(1):572.

PubMed
PubMed Central

Google Scholar
Moukoumbi Lipenguet G, Ngoungou EB, Ibinga E, Engohang-Ndong J, Wittwer J. Evaluation of direct costs associated with the management of clinical stage of malaria in children under five years old in Gabon. Malar J. 2021;20:334.

PubMed
PubMed Central

Google Scholar
Mulligan JA, Yukich J, Hanson K. Costs and effects of the Tanzanian national voucher scheme for insecticide-treated nets. Malar J. 2008;7:32.

PubMed
PubMed Central

Google Scholar
Mustafa MH, Babiker MA. Economic cost of malaria on households during a transmission season in Khartoum State. Sudan East Mediterr Health J. 2007;13(6):1298–307.

CAS
PubMed

Google Scholar
Obieche OA, Odili VU. Evaluation of cost of treatment of malaria in adults in Benin City, Nigeria: patients’ perspective. Malariaworld J. 2016;7:12.

PubMed
PubMed Central

Google Scholar
Onwujekwe O, Hanson K, Uzochukwu B, Ichoku H, Ike E, Onwughalu B. Are malaria treatment expenditures catastrophic to different socio-economic and geographic groups and how do they cope with payment? A study in southeast Nigeria. Trop Med Int Health. 2010;15:18–25.

PubMed

Google Scholar
Onwujekwe O, Uguru N, Etiaba E, Chikezie I, Uzochukwu B, Adjagba A. The economic burden of malaria on households and the health system in Enugu State southeast Nigeria. PLoS ONE. 2013;8: e78362.

CAS
PubMed
PubMed Central

Google Scholar
Onyia VU, Ughasoro MD, Onwujekwe OE. The economic burden of malaria in pregnancy: a cross-sectional study. J Matern Fetal Neonatal Med. 2020;33:92–5.

PubMed

Google Scholar
Sicuri E, Davy C, Marinelli M, Oa O, Ome M, Siba P, et al. The economic cost to households of childhood malaria in Papua New Guinea: a focus on intra-country variation. Health Policy Plan. 2012;27:339–47.

PubMed

Google Scholar
Silumbe K, Yukich JO, Hamainza B, Bennett A, Earle D, Kamuliwo M, et al. Costs and cost-effectiveness of a large-scale mass testing and treatment intervention for malaria in Southern Province. Zambia Malar J. 2015;14:211.

PubMed

Google Scholar
Stevens W, Wiseman V, Ortiz J, Chavasse D. The costs and effects of a nationwide insecticide-treated net programme: the case of Malawi. Malar J. 2005;4:22.

PubMed
PubMed Central

Google Scholar
Tawiah T, Asante KP, Dwommoh RA, Kwarteng A, Gyaase S, Mahama E, et al. Economic costs of fever to households in the middle belt of Ghana. Malar J. 2016;15:68.

PubMed
PubMed Central

Google Scholar
Yukich JO, Zerom M, Ghebremeskel T, Tediosi F, Lengeler C. Costs and cost-effectiveness of vector control in Eritrea using insecticide-treated bed nets. Malar J. 2009;8:51.

PubMed
PubMed Central

Google Scholar
Castellani J, Mihaylova B, Evers SM, Paulus AT, Mrango ZE, Kimbute O, et al. Out-of-pocket costs and other determinants of access to healthcare for children with febrile illnesses: a case-control study in rural Tanzania. PLoS ONE. 2015;10: e0122386.

PubMed
PubMed Central

Google Scholar
Orem JN, Kirigia JM, Azairwe R, Zikusooka CM, Bataringaya J, Ogwang PO. Cost of malaria morbidity in Uganda. J Econom Sustain Dev. 2012;3:58–80.

Google Scholar
Teklehaimanot A, Mejia P. Malaria and poverty. Ann NY Acad Sci. 2008;1136:32–7.

PubMed

Google Scholar